Filing Details

Accession Number:
0000899243-18-010833
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-04-26 16:44:03
Reporting Period:
2018-04-24
Accepted Time:
2018-04-26 16:44:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1589095 Versant Affiliates Fund V, L.p. One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1589097 Versant Venture Capital V, L.p. One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1589098 Versant Ophthalmic Affiliates I, L.p. One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1612235 Versant Venture Capital V (Canada), Lp One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1619298 Versant Ventures V, Llc One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2018-04-24 20,071 $51.00 1,519,505 No 4 S Indirect See footnote
Common Shares Disposition 2018-04-24 589 $50.60 44,582 No 4 S Indirect See footnote
Common Shares Disposition 2018-04-24 653 $51.00 49,419 No 4 S Indirect See footnote
Common Shares Disposition 2018-04-24 1,528 $51.00 115,645 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V").
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  3. These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.
  4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V").
  5. These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.
  6. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA").
  7. These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.
  8. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P.("VVC CAN").
  9. These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.